Aeterna Zentaris Inc. (AEZS)
- Previous Close
1.9900 - Open
1.9650 - Bid 1.4100 x 200
- Ask 2.5400 x 200
- Day's Range
1.9500 - 1.9650 - 52 Week Range
1.3600 - 3.3000 - Volume
5,085 - Avg. Volume
15,915 - Market Cap (intraday)
9.499M - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4100 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.00
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to development, manufacture, and commercialization of AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
www.zentaris.comRecent News: AEZS
Performance Overview: AEZS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AEZS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AEZS
Valuation Measures
Market Cap
9.42M
Enterprise Value
-24.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.11
Price/Book (mrq)
0.52
Enterprise Value/Revenue
-5.41
Enterprise Value/EBITDA
1.36
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.19%
Return on Equity (ttm)
-61.34%
Revenue (ttm)
4.5M
Net Income Avi to Common (ttm)
-16.55M
Diluted EPS (ttm)
-3.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
34.02M
Total Debt/Equity (mrq)
1.53%
Levered Free Cash Flow (ttm)
-10.21M